Altogen Labs A431 Xenograft Service Melanoma
Altogen Labs http://altogenlabs.com provides xenograft services http://altogenlabs.com/xenograft-mode.... The A431 cell line was derived from skin cells of an 85-year-old female patient with epidermoid carcinoma and is a suitable host for studies of skin cancer and other cancer types, as well as preclinical studies of novel therapeutics for these diseases. Preclinical studies of cell-derived xenograft animal models can help scientists find new therapies for patients with skin cancer.
The A431 human melanoma cell line is used to create the CDX (Cell Line Derived Xenograft) A431 xenograft mouse model that is sensitive to EGF inhibitor therapeutics. Preclinical studies of skin cancer can help researchers to investigate its correlation with immune response and find new therapies for patients with this disease.
Xenografting is the transplantation of tissue from one species into another.
Xenografting has been established as benchmark studies in pre-clinical cancer research.
Typically, immunodeficient mice serve as hosts for a wide variety of human tumors, effectively serving as models for human subjects.
Xenografting is a complete and accurate study of tumor growth and the activity of drug administration.
-A431 Xenograft Study
Data Endpoints
Estimated tumor volume (L x W2 /2)
Mean/median time to specified tumor volume
Survival time to specified tumor volume
Tumor doubling time
Tumor growth inhibition (TGI)
Tumor growth delay (TGD)
Increased life span (ILS)
Tumor cell kill rate
-A431 Xenograft Model
Advantages of Xenografting
Develop new therapeutic agents quickly, efficiently and cost-effectively
Evaluate the efficacy and toxicity of potential therapeutic agents
Evaluate target compound activity using in vivo system (human cells)
Predict cytotoxicity of cancer drugs
-A431 Xenograft Model
Basic Xenograft Study
Xenograft studies can be designed to:
Identify lead compounds
Optimize dose schedules
Identify combination strategies
-A431 Xenograft Model
Routes of drug administration:
Intratumoral
Intramuscular
Oral gavage
Intravenous
Intratracheal
Subcutaneous
Intraperitoneal
Continuous infusion
Intranasal
Using cutting-edge micro-injection techniques
-A431 Xenograft Model
Following options are available for the A431 xenograft model:
A431 Tumor Growth Delay (TGD; latency)
A431 Tumor Growth Inhibition (TGI)
Dosing frequency and duration of dose administration
A431 tumor immunohistochemistry
Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
Blood chemistry analysis
Toxicity and survival (optional: performing a broad health observation program)
Gross necropsies and histopathology
Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
Lipid distribution and metabolic assays
Imaging studies: Fluorescence-based whole body imaging, MRI
-A431 Xenograft Model
Altogen Labs’ team of scientists carries extensive experience in Xenograft model research.
Altogen Labs is compliant as a Good Laboratory Practices (GLP) environment, which is required by the FDA for pre-clinical research.
Our Altogen Labs’ Xenograft services are extensive, rigorous, and flexible.
Contact us to discuss Xenograft model details, timeline estimates, and price quotes!
Connect to Altogen Labs:
LinkedIn - / altogen-labs
Twitter - https://twitter.com/altogen?lang=en
Facebook - / altogen.cro